<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[RSS Feed]]></title><description><![CDATA[RSS Feed]]></description><link>https://ecency.com</link><image><url>https://ecency.com/logo512.png</url><title>RSS Feed</title><link>https://ecency.com</link></image><generator>RSS for Node</generator><lastBuildDate>Mon, 07 Sep 2026 02:57:03 GMT</lastBuildDate><atom:link href="https://ecency.com/created/anabrez1mg/rss.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Combination Therapy with Aromatase Inhibitors in Postmenopausal Breast Cancer]]></title><description><![CDATA[Combination therapy, utilizing Aromatase Inhibitors (AIs) alongside targeted agents, has emerged as one of the promising approaches in the treatment of hormone-sensitive breast cancer in postmenopausal]]></description><link>https://ecency.com/@mrmed/combination-therapy-with-aromatase-inhibitors</link><guid isPermaLink="true">https://ecency.com/@mrmed/combination-therapy-with-aromatase-inhibitors</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Sat, 16 Mar 2024 17:25:15 GMT</pubDate></item><item><title><![CDATA[Efficacy of Aromatase Inhibitors in Postmenopausal Breast Cancer Patients]]></title><description><![CDATA[Breast cancer is commonly affecting cancer in women, and it is more common in postmenopausal women who have passed over 50 years of age. Even Though there are various advanced treatments involved in treating]]></description><link>https://ecency.com/@mrmed/efficacy-of-aromatase-inhibitors-in</link><guid isPermaLink="true">https://ecency.com/@mrmed/efficacy-of-aromatase-inhibitors-in</guid><category><![CDATA[mrmed]]></category><dc:creator><![CDATA[mrmed]]></dc:creator><pubDate>Mon, 12 Feb 2024 05:42:42 GMT</pubDate></item></channel></rss>